Commercial “go-live” moments in biopharmaceutical manufacturing are often misunderstood. They are frequently framed as commercial launches or revenue milestones, when
For health systems across the Gulf, advanced therapies such as CAR-T have historically been accessed through outbound medical evacuation. Patients
Medical tourism in the Gulf is entering a new phase. The traditional model—patients flying long distances for complex oncology and
Across the GCC, ministries of health are accelerating the localization of biologics and advanced therapies. Yet as manufacturing capacity expands,
Advanced therapies such as CAR-T and other cell and gene treatments are no longer hypothetical for the Gulf. Manufacturing capability
Why Does Biologics Localization in the GCC Matter for Sovereign Capability? For more than a decade, Gulf governments have
Introduction The realm of oncology in The Middle East and North Africa (MENA) is a narrative of constant evolution, striving to meet the growing demands
Introduction The realm of oncology in The Middle East and North Africa (MENA) is a narrative of constant evolution, striving to meet the growing demands
Introduction The realm of oncology in The Middle East and North Africa (MENA) is a narrative of constant evolution, striving to meet the growing demands
Introduction The realm of oncology in The Middle East and North Africa (MENA) is a narrative of constant evolution, striving to meet the growing demands
Introduction The realm of oncology in The Middle East and North Africa (MENA) is a narrative of constant evolution, striving to meet the growing demands
Introduction The realm of oncology in The Middle East and North Africa (MENA) is a narrative of constant evolution, striving to meet the growing demands
